Related Experiment Videos
A new strategy for defining critical functional groups on heparan sulfate
Zhengliang L Wu1, Lijuan Zhang, David L Beeler
1Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Summary
This study introduces a new method to understand heparan sulfate (HS) structure-function relationships. It identifies key sulfate groups and oligosaccharide lengths essential for protein binding, like antithrombin III.
Area of Science:
- Biochemistry
- Glycobiology
- Molecular Biology
Background:
- Heparan sulfate (HS) is crucial for biological processes, mediating protein interactions in a structure-specific manner.
- Understanding the precise functional groups on HS involved in protein binding is challenging due to technical limitations.
- HS interactions are vital for numerous cellular functions and disease pathways.
Purpose of the Study:
- To develop a rapid, sensitive, and cost-effective strategy for studying HS structure-function relationships.
- To identify critical structural determinants on HS required for specific protein interactions.
- To demonstrate the utility of this approach for generating biologically active HS analogs.
Main Methods:
- Utilized in vitro enzymatic modification of HS with pure enzymes.
- Employed gel mobility shift assays to assess protein-HS binding.
- Regenerated specific HS binding sites on modified heparin to identify critical enzymes.
Main Results:
- Demonstrated the necessity of 3-O and 6-O sulfates, along with minimal oligosaccharide length, for antithrombin III (AT-III) binding.
- Successfully regenerated AT-III binding sites on desulfated and N-resulfated heparin.
- Confirmed the general applicability of the method using fibroblast growth factor (FGF) and its receptors.
Conclusions:
- The developed strategy offers a powerful tool for dissecting HS-protein interactions.
- Identified critical functional groups and structural requirements for AT-III binding to HS.
- This approach facilitates the creation of HS libraries and the design of HS-based therapeutics, including anticoagulants and antiviral agents.